



AURORA[®]



Aurora Europe

Leading the way in medical cannabis

Aurora - a world-leading company with a mission

Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets. Headquartered in Canada, and with a strong international footprint, Aurora is a pioneer in global cannabis dedicated to helping people improve their lives.

Today, our indoor growing facilities lead the industry in scale, automation and efficiency, and are designed to meet EU Good Manufacturing Practices (EU-GMP) and sustainability standards.

With a focus on research and science, we are committed to clinical research and advancing innovations. Partnering with leading healthcare institutions, patient groups and cannabis associations, we are committed to studying how medical cannabis can help to improve patients' lives.


With an experienced and growing global team, we work closely with government, healthcare practitioners, researchers and policymakers across Europe and around the world to break down barriers and help build better legal frameworks for increased regulated access to medical cannabis. We are dedicated to ensuring that patients receive access to medicines from which they might benefit.



Leading in Europe

Aurora's European headquarters are in Berlin, Germany, with our state-of-the-art growing facility based in Odense, Denmark. We have become the largest authorized importer and distributor of medical cannabis in the European Union. Our cannabis production and distribution facilities are certified under EU Good Manufacturing Practice and are critical to our success in Europe.

With a fast-growing organization across Germany and the EU, Aurora has held a leading market share in the German medical cannabis market since 2015. With a population of over 500 million, Europe remains a key focus for the Group and we now distribute to nine markets across the region.



Selected Milestones

- Our subsidiary in GERMANY supplies products to all other countries in our European network and has secured one of three Federal licenses to cultivate and distribute medical cannabis in Germany. Aurora is market leader in the dried flower market segment.
- In DENMARK, we were the first to ship medical cannabis to the Danish Medical Cannabis Pilot program. Aurora Nordic is an EU-GMP high-tech cultivation facility producing medical cannabis products for Aurora's European and international markets.
- In POLAND, we were the first cannabis company to gain a comprehensive marketing authorization for a wide range of therapy options and now deliver a portfolio of products nationwide.
- In the UNITED KINGDOM, we were among the first companies who gained approval to ship medical cannabis.

- In FRANCE, we were the first foreign cannabis company with a legal affiliate and a team on the ground in 2019. In 2021, Aurora was selected, together with Ethypharm, as the primary source for the entire supply of medical cannabis dried flowers in the French government pilot program.
- In ITALY, we were the sole winner for two public tenders to supply medical cannabis nationwide in 2019.
- In the CZECH REPUBLIC, as one of the first LPs, we supply medical cannabis to pharmacies nationwide via a local wholesaler.
- In LUXEMBOURG, we won the first exclusive Health Ministry tender for medical cannabis in 2018.
- In MALTA, we were the first company to ship medical cannabis.

Advancing science to progress medical cannabis as choice of treatment for physicians

Aurora has been actively involved in several observational trials and case studies, of which many have, or are being conducted in partnership with academic research institutions and world-renowned hospitals. Areas include: Pain, epilepsy, PTSD, anxiety, opioid/harm reduction, cancer, neurodegenerative diseases, and others. We leverage our cannabis science expertise to cultivate new and unique cultivars, helping us to address evolving demands.

For some years now, there has been a resurgence in research, as a result of international narcotic laws prohibiting the study of cannabis-based medicines for much of the 1900s. Medical cannabis is not just one product, but a group of products, each with different properties: it is critical to study the different levels of active ingredients and the interaction between these to understand the potential for effects on diseases.

As the sentiment on cannabis changed, the number of scientific publications increased exponentially. In 2015, there were 1,600 publications in the entire year. In 2020, this number went up to 2,300 publications: a clear trend that cannabis research is growing stronger.





Shaping medical cannabis markets – selected activities

Improving access in the UK

Shortly after the change in legislation in November 2018, Aurora became one of the first companies to supply medical cannabis to the UK. Since then, patient numbers have increased rapidly, although access remains difficult. Physician education, National Institute for Health and Care Excellence (NICE) recommendations, stigma and a lack of reimbursement are all factors that continue to limit the number of medical cannabis prescriptions to many patients who might benefit.

Aurora is at the forefront of helping to unlock the potential of the market and we are working hard to develop a more efficient and accessible medical cannabis system. To achieve this, we have established ourselves as a trusted partner for physicians, patients and regulatory authorities by continuing to supply pharmaceutical-grade medicine to our patients. We are also investing in clinical research, physician education and continued patient advocacy, all of which we expect will create a framework that enables patients' access to affordable cannabis-based medicines to help improve the quality of their lives.

Establishing a new market in France

In 2021, France launched a two-year pilot program that will allow medical cannabis to be prescribed to patients with certain severe conditions. Together with our partner Ethypharm, we were selected by the National Agency for the Safety of Medicines and Health Products (ANSM) to supply the entire medical cannabis dried flower range (three lots of the tender) to French patients. If successful, this pilot program could lead to one of the largest regulated medical cannabis markets in Europe.

Production in Denmark for Europe

The EU-GMP certified production site Aurora Nordic in Odense, Denmark, is the first and largest facility of the company in Europe. With a maximum capacity of 10,000 kg per year, we anticipate it will be possible to serve the European demand for medical cannabis over the short to medium term. In addition to dried flowers and full extracts with different THC and CBD contents, other formulations for medical needs can also be produced at Aurora Nordic in the future. The advantages of this facility are clear: short delivery routes and lower logistics costs, as well as faster adaptation options to meet the needs of the markets in Europe.

EU-GMP certification: Ensuring pharmaceutical-grade, consistent medicines

Aurora is committed to the highest quality standards with its medicines, as dictated by the directives and laws within the EU for medical products. In our global network, we have production facilities - currently in Canada and Denmark - that are certified according to EU Good Manufacturing Practice (EU-GMP). Established standard procedures, full automation of temperature, air purity and humidity, as well as defined lighting duration and intensity result in high quality and consistent active ingredient concentrations which is critical in ensuring patient safety.



Production in Denmark

Better lives and increased access for patients.

We believe, and a growing body of evidence, shows that medical cannabis can improve the lives of many people. This drives our commitment for a world where patients have access to the products they need, without stigma or prosecution.

Our lobby and advocacy work in Europe is based on seven key umbrella goals:

- Improved legal status for medical cannabis and safe access for patients in need.
- Consistent reimbursement and fair costs for prescribed cannabis medicine.
- Quality education and harmonized medical cannabis guidelines for healthcare professionals.
- Fair market access for licensed cannabis companies (single EU market rules).
- Adherence to mandated EU-GMP quality standards that are applied consistently within and across EU member states.
- Enhanced public funding for cannabis research and evidence studies.
- Balanced presentation of risks and benefits of medical cannabis in public education.



To achieve our mission, we drive the public dialogue, engage in political debates and raise awareness with various stakeholders through our involvement in numerous associations. We also raise awareness through research and development, to make cannabis a trusted treatment for all those in need.

As a responsible citizen and employer, we respect and support the dignity and well-being of our employees, the communities where we live and work, and those impacted by our operations, products and business relationships.

We advocate for fairer systems - in the interest of cannabis patients in need. #BetterDays #AuroraEngage

For more information, please visit our website

www.auroramedicine.com



AURORA®

Aurora Deutschland GmbH

Wilmsdorfer Str. 98/99 | 10629 Berlin | Deutschland

Telefon: +49 (0)30 9832 1601- 0 | Fax: +49 (0)30 9832 1601- 9

E-Mail: contact@auroramedicine.com

www.auroramedicine.com